Latest news

Останні новини

thumbnail_Group 642.png

Group 642.png

ALKALOID: Consolidated sales of EUR 168 million, investments of EUR 13.6 million, and 43 new jobs created in the country during the period January–June 2026.&nbsp;

ALKALOID – Financial Results for the Period January–June 2026

From February 26 to March 1, 2026, the XVIII Academic School of Pediatrics took place in the picturesque Carpathian region. This time, the event was held in a hybrid format, combining both offline and online participation.

XVIII Academic School of Pediatrics

The Pediatrics &amp; Allergology Hub Conference Spring 2026, held on March 7, 2026, in an offline format, served as a professional platform for discussing current issues in modern pediatrics, allergology, infectious pathology, and daily clinical practice. The event's exceptional value was driven by insightful presentations, clinical highlights, practical cases, and lively professional discussions between speakers and the audience.

Pediatrics & Allergology Hub Conference Spring 2026

ALKALOID achieved record consolidated sales of EUR 339.3&nbsp;million, consolidated exports of EUR 221.6&nbsp;million, and invested EUR 18 million in the January – December 2025 period.

ALKALOID – Operating Results for the January – December 2025 period

At the beginning of the year, Alkaloid Ukraine held its Winter Kick-Off Meeting in Truskavets, a renowned spa city in the Carpathian region of Ukraine. Known for its healing waters and calm atmosphere, Truskavets created the right environment for strategic reflection, professional development, and meaningful team interaction. Stepping away from everyday operational routines allowed the team to focus on long-term goals, shared values, and the challenges ahead.

Alkaloid UA Winter Kick-Off Meeting 2026:  Results, Learning, and Shared Responsibility for the Future

Alkaloid UA Winter Kick-Off Meeting 2026

The primary purpose of the Microbiological Quality Control Laboratory – Alkaloid AD’s latest €3.1 million investment – is to deliver the highest standards of microbiological quality control across raw materials, primary packaging, intermediates, and finished products.

ALKALOID’S NEW MICROBIOLOGICAL QUALITY CONTROL LABORATORY COMMISSIONED DURING OFFICIAL GOVERNMENT DELEGATION VISIT

As the holder of the first international value-added medicine patent – liquid&nbsp;Omeprazole, ready to use – Alkaloid sponsored the First International Conference on Modern Approaches to GERD Treatment in Pediatric Patients, held in Zagreb, Croatia.

ALKALOID OPENS NEW HORIZONS IN GERD TREATMENT WITH LIQUID OMEPRAZOLE: FIRST INTERNATIONAL CONFERENCE ON INNOVATIVE SOLUTIONS IN PEDIATRIC GERD TREATMENT HELD IN ZAGREB

ALKALOID OPENS NEW HORIZONS IN GERD TREATMENT WITH LIQUID OMEPRAZOLE

ALKALOID reached consolidated sales of EUR 84.5 million, consolidated export of EUR 57.4 million and invested EUR 4.2 million in the January – March 2025 period.

Visit your local Alkaloid website

Serbia

Romania

Croatia

Ukraine

Bulgaria

Bosnia and Herzegovina